Multimodal treatment in oligometastatic gastric cancer

Chevallay, Mickaël; Wassmer, Charles-Henri; Iranmanesh, Pouya; Jung, Minoa; Mönig, Stefan P.

doi:10.4251/wjgo.v14.i2.434

Cited by 12 publications

(17 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that radical resection could bene t highly selected oligometastatic gastric cancer patients [29,30]. Indeed, it has been reported that PFS of 25.5 months reached in 13 patients with metastatic disease (P1 or CY1) who achieved P0 or CY0 after chemotherapy and underwent R0 gastrectomy [31].…”

Section: Discussionmentioning

confidence: 99%

Does resection after neoadjuvant chemotherapy of Docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA)

Cui

Zheng

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The Neo-REGATTA study evaluated the effectiveness and safety of Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection vs. chemotherapy in advanced gastric adenocarcinoma patients with single non-curable factor. Methods This cohort study prospectively enrolled advanced gastric adenocarcinoma patients with single non-curable factor between November 2017 and June 2021. Patients without progression after four cycles of DOS were divided into resection group and chemotherapy group. The outcomes included overall survival (OS), progression-free survival (PFS) and safety. Effectiveness analysis was also performed by propensity score matching (PSM). Results A total of 73 patients were enrolled and 13 patients were withdrawn due to disease progression after 4 cycles of DOS. Afterwards, 35 and 25 participants were in the resection and chemotherapy groups, respectively. After a median follow-up time of 19.5 months (5–48 months), the median PFS and OS were 9.0 months, and 18.0 months for the chemotherapy group, but not reached in the resection group. After PSM, 19 matched participants were in each group. The OS was longer in resection group than that in chemotherapy group (HR = 0.19, 95% CI: 0.05–0.70, P = 0.013). The PFS was longer in resection group than that in chemotherapy group (HR = 0.22, 95% CI: 0.07–0.68, P = 0.009). The most common grade 3 or 4 adverse events in both groups were neutropenia (5.7%, 8.0%) and leukopenia (5.7%, 8.0%), respectively. Conclusions Radical resection might provide survival benefit compared with continuous chemotherapy alone in advanced gastric adenocarcinoma patients who had a disease control after DOS, with a good safety profile. Trial registration: The study protocol was registered on ClinicalTrial.gov (NCT03001726, 23/12/2016).

show abstract

Section: Discussionmentioning

confidence: 99%

Does resection after neoadjuvant chemotherapy of Docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA)

Cui

Zheng

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that radical resection could benefit highly selected oligometastatic gastric cancer patients [ 29 , 30 ]. Indeed, it has been reported that PFS of 25.5 months reached in 13 patients with metastatic disease (P1 or CY1) who achieved P0 or CY0 after chemotherapy and underwent R0 gastrectomy [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Cui

Zheng

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background The Neo-REGATTA study evaluated the effectiveness and safety of Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection vs. chemotherapy in advanced gastric adenocarcinoma patients with single non-curable factor. Methods This cohort study prospectively enrolled advanced gastric adenocarcinoma patients with single non-curable factor between November 2017 and June 2021. Patients without progression after four cycles of DOS were divided into resection group and chemotherapy group. The outcomes included overall survival (OS), progression-free survival (PFS) and safety. Effectiveness analysis was also performed by propensity score matching (PSM). Results A total of 73 patients were enrolled and 13 patients were withdrawn due to disease progression after 4 cycles of DOS. Afterwards, 35 and 25 participants were in the resection and chemotherapy groups, respectively. After a median follow-up time of 30.0 months, the median PFS and OS were 9.0 months, and 18.0 months for the chemotherapy group, but not reached in the resection group. After PSM, 19 matched participants were in each group, and the median PFS and OS were longer in resection group than that in chemotherapy group. The most common grade 3 or 4 adverse events both in the resection group and chemotherapy groups were neutropenia (5.7%, 8.0%) and leukopenia (5.7%, 8.0%). Conclusions Radical resection might provide survival benefit compared with continuous chemotherapy alone in advanced gastric adenocarcinoma patients who had a disease control after DOS, with a good safety profile. Trial registration The study protocol was registered on ClinicalTrial.gov (NCT03001726, 23/12/2016).

show abstract

“…treatment for cancer experiences a recurrence in a limited number of locations in the body [11]. Appropriate localized treatment could prolong survival in selected patients [12], while treatment consensus for oligorecurrence of gastric cancer has not been established.…”

Section: Discussionmentioning

confidence: 99%

“…The present case was considered as repeat oligorecurrence, which refers to a situation where a cancer patient who has previously undergone treatment for cancer experiences a recurrence in a limited number of locations in the body [ 11 ]. Appropriate localized treatment could prolong survival in selected patients [ 12 ], while treatment consensus for oligorecurrence of gastric cancer has not been established.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival After Repeated Salvage Chemoradiation Therapy for Metastatic Lymph Node Recurrence in Advanced Gastric Cancer: A Case Report

Katano¹,

Yamashita²

2023

Cureus

View full text Add to dashboard Cite

Metastatic recurrence in advanced gastric cancer is a poor prognosis, and where recently novel systemic therapies have been investigated. This case report describes the successful use of repeated salvage chemoradiation therapy in a patient with advanced gastric cancer who had failed initial treatments. The patient achieved long-term survival and remained disease-free for several years after treatment. The report highlights the potential benefits of salvage chemoradiation therapy in selected patients with advanced gastric cancer and the need for further studies to determine the optimal treatment approach for these patients. The report also discusses recent promising results from clinical trials of combination regimens with immune checkpoint inhibitors and targeted therapies in the management of advanced gastric cancer. Overall, the report highlights the ongoing challenge of managing advanced gastric cancer and the importance of personalized treatment strategies.

show abstract

Multimodal treatment in oligometastatic gastric cancer

Cited by 12 publications

References 81 publications

Does resection after neoadjuvant chemotherapy of Docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA)

Does resection after neoadjuvant chemotherapy of Docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? A multicenter, prospective cohort study (Neo-REGATTA)

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Long-Term Survival After Repeated Salvage Chemoradiation Therapy for Metastatic Lymph Node Recurrence in Advanced Gastric Cancer: A Case Report

Contact Info

Product

Resources

About